All News

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

Richard T. Maziarz, MD, and a team of investigators assessed average medical costs of allo-HCT throughout a patient’s lifetime and the net monetary savings and value associated with reducing complications.

The FDA clinical reviewer responsible for the approval of this combination therapy discusses the data that led to the approval in May 2022.

It remains a challenge to understand how to stratify risk of liver diseases before they have reached the advanced stage.

Phase 1 clinical trial data show the drug to be active with evidence of clinically meaningful responses and a manageable safety profile.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Regular physical activity helps to facilitate a healthy gut microbiome and lowers inflammation, which were observed in patients independent of body mass index.

Prior research indicates a platelet-based connection between migraine and the patent foramen ovale.

Relatives who attend low-intensity coaching and monitoring meetings increase individuals’ ability to manage the disease.

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.

Although patients with Richter syndrome often experience poor outcomes, there are many new treatment strategies that have demonstrated a durable response.

Five crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Herpes zoster and postherpetic neuralgia can cause a significant health burden among adults 65 years of age and older.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Lead compounds may lower the risk of abuse and other adverse effects compared with other drugs currently being evaluated for mental health disorders, such as MDMA.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

A patient with juvenile dermatomyositis experienced aseptic meningitis brought on by intravenous immunoglobulin and recovered fully with no neurological effects.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

Low socioeconomic status was associated with greater in-hospital mortality and decreased use of advanced therapeutic options.

In recent decades, clinical trials have grown increasingly restrictive and exclusive, which has impacted the inclusivity and diversity of selected trial participants.

Following a phase 2 analysis of OP-1250 with palbociclib, researchers recommend an OP-1250 dose level of 120 mg/day for future trials.

Guidelines for HER2-low expressed cancer could define who and how patient recieve drugs, said expert live from San Antonio Breast Cancer Symposium 2022.

At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.